Soleno Therapeutics, Inc.

Thank you. Thank you. Thank you. Thank you. Thank you. Thank you.

Good afternoon and thank you for standing by. Welcome to Solano Therapeutics' fourth quarter and full year 2025 financial and operating results conference call and webcast. Currently, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. As a reminder, today's webcast is being recorded. I would now like to introduce Brian Ricci of LifeSci Advisors. Please go ahead.

Thank you. Good afternoon everyone and thank you for joining us to discuss Thelena therapeutics, 4th, quarter and full year 2025 financial and operating results. Please note, we'll be making certain forward looking statements today. We refer you to fileings for a discussion of the risks that may cause actual results to differ from the forward looking statements. On the call with me today for Celeno are Anish Bhatnagar, Celeno's Chairman and Chief Executive Officer, Meredith Manning, Celeno's Chief Commercial Officer, and Jim McInnes, Celeno's Chief Financial Officer. With that, I will now turn the call over to Anish.